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C A N C E R
Autophagy suppresses the formation of  
hepatocyte-derived cancer-initiating ductular 
progenitor cells in the liver
Valentin J. A. Barthet1,2*, Martina Brucoli1,2, Marcus J. G. W. Ladds1, Christoph Nössing1,2, 
Christos Kiourtis1,2, Alice D. Baudot1, James O’Prey1, Barbara Zunino1, Miryam Müller1, 
Stephanie May1, Colin Nixon1, Jaclyn S. Long1, Thomas G. Bird1,3, Kevin M. Ryan1,2*
Hepatocellular carcinoma (HCC) is driven by repeated rounds of inflammation, leading to fibrosis, cirrhosis, and, ulti-
mately, cancer. A critical step in HCC formation is the transition from fibrosis to cirrhosis, which is associated with a 
change in the liver parenchyma called ductular reaction. Here, we report a genetically engineered mouse model of HCC 
driven by loss of macroautophagy and hemizygosity of phosphatase and tensin homolog, which develops HCC 
involving ductular reaction. We show through lineage tracing that, following loss of autophagy, mature hepatocytes 
dedifferentiate into biliary-like liver progenitor cells (ductular reaction), giving rise to HCC. Furthermore, this change 
is associated with deregulation of yes-associated protein and transcriptional coactivator with PDZ-binding motif 
transcription factors, and the combined, but not individual, deletion of these factors completely reverses the 
dedifferentiation capacity and tumorigenesis. These findings therefore increase our understanding of the cell of origin 
of HCC development and highlight new potential points for therapeutic intervention.
INTRODUCTION
Liver cancer is predicted to be the third leading cause of cancer-related 
deaths by 2030 (1). Hepatocellular carcinoma (HCC) is the major 
form of liver cancer and develops in patients with chronic liver con-
ditions, including viral hepatitis, as well as alcoholic and nonal-
coholic fatty liver disease (2). Generally, chronic liver injuries lead 
to inflammation, stromal activation, regeneration, fibrosis, and cir-
rhosis before progression to HCC (3).
Autophagy (strictly macroautophagy but hereafter referred to 
simply as autophagy) is a catabolic membrane-trafficking process 
that serves to deliver cellular constituents including misfolded pro-
teins and damaged organelles to lysosomes for degradation (4). There 
is now clear evidence that autophagy is important in various diseases 
including neurodegenerative diseases, chronic liver diseases, and 
cancer (5–7). The role of autophagy in cancer, however, is complex 
and not fully understood, with seemingly opposing roles described 
in different tumors and at different stages of tumor evolution (8–12). 
In the early stages of malignant transformation, autophagy removes 
damaged mitochondria responsible for the production of reactive 
oxygen species (ROS) (13) and prevents genomic instability (14), 
highlighting its role in preventing tumor initiation. Conversely, in 
established tumors, autophagy not only can adopt a protumorigenic 
role, for example, by promoting survival under hypoxic conditions (15) 
and supporting invasion and metastasis (16), but also can have a 
tumor-suppressive role by preventing the proliferative outgrowth of 
disseminated tumor cells from dormant states at metastatic sites (17–19).
In the liver, autophagy has primarily been described as tumor 
suppressive (11). Liver-specific deletion of the central autophagy- 
related protein 5 (ATG5) or ATG7 in mice leads to the formation of 
liver steatosis, inflammation, ROS production, oval cell formation, 
fibrosis, hepatomegaly, and the development of HCCs (11, 20). In 
many cases, loss of autophagy causes accumulation of the autopha-
gy adapter protein p62 (Sqstm1), and this can influence antioxidant 
responses by affecting the axis between Kelch-like ECH-associated 
protein 1 (KEAP1) and nuclear factor (erythroid-derived 2)-like 2 
(NRF2) (21). In autophagy-deficient livers, studies have shown that 
p62 accumulation activates the NRF2 signaling pathway to induce 
metabolic reprogramming, hepatomegaly, and tumorigenesis (22, 23).
The liver is a plastic organ in which cell fate can change upon 
injuries to regenerate liver function loss. Hepatocytes and cholan-
giocytes, epithelial cells that form the liver parenchyma and the bile 
duct, respectively, can transdifferentiate into one another to reestab-
lish bile duct or liver parenchyma functions (24, 25), with hepato-
cytes being the primary source of liver regeneration upon injury. 
Following chronic injury, ductular cells develop in the liver paren-
chyma when hepatocyte or cholangiocyte function is severely im-
paired, a process called ductular reaction (26). The ductular reaction 
is a repair mechanism for generating new hepatocytes or cholangio-
cytes, depending on which liver cells are injured (27). However, the 
origin of the ductular reaction and its role in liver tumorigenesis 
are controversial with reports indicating that ductular cells can arise 
from cholangiocyte expansion (28, 29) or through hepatocyte dedif-
ferentiation (30, 31) and reports concluding that the ductular reac-
tion is involved in forming HCC (32, 33), while other studies report 
the opposite (34, 35). Autophagy-deficient livers undergo a ductu-
lar reaction (36), and we considered this as an excellent system in 
which to explore its origin and the role, this phenomenon plays in 
tumorigenesis.
In this study, we report that autophagy prevents hepatocyte 
dedifferentiation into ductular liver progenitor cells (LPCs). This ductu-
lar LPC population affects HCC formation in autophagy-deficient 
livers. Mechanistically, we show that autophagy deletion activates both 
yes-associated protein (YAP) and transcriptional coactivator with 
PDZ-binding motif (TAZ) in hepatocytes, which are connected 
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to the ductular reaction leading, ultimately, to tumorigenesis. We 
show that YAP/TAZ coexpression is required to trigger the ductu-
lar reaction and tumorigenesis in autophagy-deficient livers.
RESULTS
Phosphatase and tensin homolog deficiency accelerates 
the establishment of a tumor-prone microenvironment 
in autophagy-deficient livers
Autophagy loss in the murine liver results in hepatomegaly, inflam-
mation, and fibrosis leading to the formation of liver HCCs at 
12 months of age (20). Phosphatase and tensin homolog (PTEN) 
expression is lost in approximately half of human liver cancers, and 
hepatic Pten-deficient mice develop HCC at 74 weeks (37). To 
accelerate the autophagy phenotype in the liver, we used the liver- 
specific promoter Albumin-Cre to selectively delete either Atg7flox/flox 
or Atg5flox/flox in the liver in combination with either heterozygous 
Pten+/flox (Alb-Cre+; Atg7fl/fl; Pten+/fl or Alb-Cre+; Atg5 fl/fl; Pten+/fl) 
or homozygous Pten flox/flox (Alb-Cre+; Atg7fl/fl; Ptenfl/fl or Alb-
Cre+; Atg5fl/fl; Ptenfl/fl). The reduced gene dosage of Pten in 
an autophagy-deficient background significantly decreased mouse 
life span similarly in males and females (Fig. 1A and fig. S1A). At 
end point, while Alb-Cre+; Atg7fl/fl; Pten+/fl and Alb-Cre+; Atg5fl/fl; 
Pten+/fl mice developed liver HCCs (Fig. 1B and fig. S1B), Alb-Cre+; 
Atg7fl/fl; Ptenfl/fl and Alb-Cre+; Atg5fl/fl; Ptenfl/fl mice were culled be-
cause of extensive hepatomegaly and did not form tumors. To eval-
uate whether the decreased survival of Alb-Cre+; Atg7fl/fl; Pten+/fl 
and Alb-Cre+; Atg5fl/fl; Pten+/fl mice was a result of an early tumor 
onset, we compared the tumorigenesis of Pten+/+ and Pten+/fl mice 
with an autophagy-deficient background at 140 days. This revealed 
that heterozygous deletion of Pten significantly accelerated tumori-
genesis in autophagy-deficient livers (Fig. 1, B and C, and fig. S1, B 
and C). Although conditional double knockout mice did not develop 
HCC at end point (4 to 5 weeks), they presented with excessive liver 
overgrowth. When we compared the liver size in 4- to 5-week-old 
mice, we observed that PTEN loss significantly increased the hep-
atomegaly of autophagy-deficient livers (Fig. 1D and fig. S1D).
Next, we assessed whether PTEN loss promotes early develop-
ment of a tumor-permissive microenvironment in 4- to 5-week-old 
autophagy-deficient livers by looking for markers of inflammation 
(38) and fibrosis. This showed that both hemizygous and homozy-
gous Pten deletion significantly increased the recruitment of Ly6G+ 
neutrophils (Fig. 1E and fig. S1E) and activated –smooth muscle 
actin+ (-SMA+) expressing hepatic stellate cells (Fig.  1E and fig. 
S1F) in the parenchyma of autophagy-deficient livers, concomitant 
with a significantly enhanced collagen deposition (Fig. 1E and fig. 
S1G). PTEN deficiency in 4- to 5-week-old autophagy-competent 
livers (Alb-Cre+; Pfl/fl) did not result in hepatomegaly, inflamma-
tion, hepatic stellate cell activation, or fibrosis (Fig. 1, D and E, 
and fig. S1, D to G). Together, our data suggest that PTEN loss ac-
celerates the early formation of a tumor-prone microenvironment 
(inflammation, hepatic stellate cell activation, and fibrosis) and 
tumorigenesis in autophagy-deficient livers.
Autophagy prevents hepatocyte dedifferentiation into 
ductular LPCs
Following histological examination, we observed an accumulation 
of atypical ductular structures in the parenchyma of conditional double 
knockout livers (Fig. 1E), called ductular reaction. Under normal 
con ditions, the liver has ductular structures, called the bile duct, that 
are formed out of cholangiocytes (Fig. 1E). The ductular reaction is 
a regeneration program that occurs in the liver following chronic 
liver injury that impairs the hepatocyte capacity to regenerate the 
liver (27). To evaluate whether hepatocytes are injured upon loss of 
autophagy, we first assessed the expression of enzymes for liver dam-
age in the serum of 4- to 5-week-old livers. All autophagy-deficient 
livers had a significant increase in alkaline phosphatase (ALP), 
alanine aminotransferase (ALT), aspartate aminotransferase (AST) and 
-glutamyl transferase (GGT) levels in comparison to wild-type 
(WT) (Alb-Cre+; Atg7+/+ or Atg5+/+; Pten+/+) mice (Fig. 2A and fig. 
S2, A to D). In addition, we determined whether hepatocytes were dy-
ing in our model by looking for cells positive for cleaved caspase 3 
(CC3), a marker of apoptosis. We noted a significant augmentation 
of CC3+ hepatocytes in 4- to 5-week-old autophagy-deficient livers 
when compared to WT livers (Fig. 2, B and C, and fig. S2E), indicating 
that autophagy prevents hepatocyte cell death. Next, we observed a 
significant accumulation of the ductular markers sex-determining 
region Y-box 9 (SOX9), cytokeratin-19 (CK19), and panCK in Alb-Cre+; 
Atg7fl/fl; Ptenfl/fl or Alb-Cre+; Atg5fl/fl; Ptenfl/fl livers in comparison to 
Alb-Cre+; Atg7fl/fl; or Alb-Cre+; Atg5fl/fl single knockout counter-
parts (Fig. 2, B and D to F, and fig. S2, F to H), confirming that the 
ductular reaction is occurring in our accelerated model.
As the ductular reaction is a regenerative process for the de novo 
generation of hepatocytes upon chronic liver injury (28–31), we 
hypothesized that ductular cells in our model are LPCs forming to 
repair injured hepatocytes. To test this, we first looked at the expres-
sion of liver stem cell markers in Atg- and Pten-deficient livers and 
found increased levels of epithelial cell adhesion molecule (EpCAM), 
CD133, and CD44 within ductular cells (Fig. 3A and fig. S3, A to C) 
of autophagy-deficient livers. The expression of the stem cell makers 
was autophagy dependent but PTEN independent (Fig. 3A and 
fig. S3, A to C), although Pten deletion appears to exacerbate the 
phenotype caused by Atg5 or Atg7 deletion. In addition, we assessed 
the expression of -fetoprotein (AFP), a fetal marker reexpressed 
during HCC and liver stem cell regeneration (39). We observed a 
significant increase in Afp mRNA levels (Fig. 3B and fig. S3D) and 
AFP protein level in the serum (Fig. 3C and fig. S3E) of autophagy- 
deficient mice when compared to WT counterparts.
We were interested to know how the ductular-reactive cells were 
forming within the liver parenchyma. It has been established that 
ductular-reactive cells can originate from dedifferentiated hepato-
cytes in the parenchyma (30, 31) or from the activation and the pro-
liferation of hepatic progenitor cells from the canal of Hering to 
regenerate the liver parenchyma when the regenerative function of 
hepatocytes is impaired (29). To determine the cell of origin for the 
ductular-reactive cells in our model, we crossed Alb-Cre−; Atg7fl/fl; 
Ptenfl/fl or Alb-Cre−; Atg5fl/fl; Ptenfl/fl mice with the double reporter 
Rosa26LoxP-Tomato-LoxP-GFP (Rosa26mTmG) and caused Cre-mediated 
recombination only in hepatocytes using the AAV8-TBG-Cre adeno- 
associated virus (AAV) (Fig. 3D and fig. S3F), where the Cre recom-
binase is expressed under the hepatocyte-specific thyroxine binding 
globulin (TBG) promoter (29). Following recombination, green 
fluorescent protein (GFP) will only be expressed in hepatocytes at 
the membrane, while non-recombined cells and unaffected tissues 
will remain Tomato+. Using this approach, we found that SOX9+ 
ductular-reactive cells expressed GFP at the membrane 40 days fol-
lowing AAV8-Cre infection in autophagy-deficient livers (Fig. 3E), 
confirming the hepatocyte origin of the ducts (fig. S3G). Together, 
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Fig. 1. Pten deletion accelerates hepatomegaly, the establishment of a tumor-prone microenvironment, and tumorigenesis in Atg7-deficient livers. (A) Kaplan-Meier 
analysis comparing overall survival of mice between males and females (left), males only (middle), or females only (right) (n = 6 males and n = 7 females per group). 
Data were analyzed by log-rank Mantel Cox test (***P < 0.001 and ****P < 0.0001). (B) Macroscopic pictures from a representative Alb-Cre+; Atg7fl/fl (Alb-Cre+; 7fl/fl) (top) and 
Alb-Cre+; Atg7fl/fl; Pten+/fl (Alb-Cre+; 7fl/fl; P+/fl) (bottom) liver in 140-day-old mice. (C) Quantification of tumor numbers in Alb-Cre+; 7fl/fl and Alb-Cre+; 7fl/fl; P+/fl at 
140 days. Data are means ± SD of six mice per group and were analyzed by Mann-Whitney test (**P < 0.01). (D) Liver-to-body weight ratio in 4- to 5-week-old mice. Data 
are means ± SD of five mice per group and were analyzed by one-way analysis of variance (ANOVA) with Tukey correction for multiple comparison tests (***P < 0.001 and 
****P < 0.0001). Please note that data are the same controls for WT and Alb-Cre+; Pfl/fl mice as shown in fig. S1D. (E) Hematoxylin and eosin (H&E) staining and immuno-
histochemical (IHC) analysis of neutrophil recruitment (Ly6G), hepatic stellate cell activation (-SMA), and collagen deposition (Sirius Red) on paraffin- embedded 
sections of livers from 4- to 5-week-old mice. Red arrowhead represents ductular structures. Scale bars, 50 m. Left: Representative staining. Right: Quantifications. 
Data are means ± SD of four or five mice per group and were analyzed by one-way ANOVA with Tukey correction for multiple comparison tests (*P < 0.05, **P < 0.01, and 
****P < 0.0001). All data points are the mean from five pictures per mouse. FoV, field of vision. Please note that data are the same controls for WT and Alb-Cre+; Pfl/fl 
mice as shown in fig. S1 (E to G).
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Fig. 2. Pten deletion accentuates liver damage and the ductular reaction in ATG7-deficient livers. (A) Serum analysis of the liver damage markers ALP, ALT, AST, and 
GGT levels in 4- to 5-week-old mice. Data are means ± SD of three to five mice per group and were analyzed by one-way ANOVA with Dunnett correction for multiple 
comparison tests (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). Please note that data are the same controls for WT and Alb-Cre+; Pfl/fl mice as shown in fig. S2 (A 
to D). (B) IHC analysis of cell death (CC3) and the duct markers SOX9, CK19, and panCK on paraffin-embedded sections of livers from 4- to 5-week-old mice. Scale bars, 
50 m. (C to F) Quantification of CC3 (C), SOX9 (D), CK19 (E), and panCK (F) from (B). Data are means ± SD of five mice per group and were analyzed by one-way ANOVA with 
Tukey correction for multiple comparison tests (**P < 0.01, ***P < 0.001, and ****P < 0.0001). All data points are the mean from five pictures per mouse. Please note data 
are the same controls for WT and Alb-Cre+; Pfl/fl mice as shown in fig. S2 (E to H).
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Fig. 3. ATG7 prevents hepatocyte dedifferentiation into LPCs. (A) IHC analysis of the liver stem cell markers EpCAM, CD133, and CD44 on paraffin-embedded sections 
of livers from 4- to 5-week old mice. Left: Representative staining. Scale bars, 50 m. Right: Quantifications. Data are means ± SD of five mice per group and were analyzed 
by one-way ANOVA with Tukey correction for multiple comparison tests (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001). All data points are the mean were from 
five pictures per mouse. Please note that data are the same controls for WT and Alb-Cre+; Pfl/fl mice as shown in fig. S3 (A to C). (B) Quantitative reverse transcription poly-
merase chain reaction (RT-PCR) analysis of Afp mRNA isolated from 4- to 5-week-old livers. 18S was used as the internal amplification control. Data are means ± SD of three 
mice per group and were analyzed by one-way ANOVA with Tukey correction for multiple comparison tests (**P < 0.01 and ****P < 0.0001). All data points are the mean 
from technical triplicates. CT, cycle threshold. (C) Enzyme-linked immunosorbent assay (ELISA) analysis of AFP from the serum of 4- to 5-week-old mice. Data are means ± SD 
of three mice per group and were analyzed by one-way ANOVA with Dunnett correction for multiple comparison tests (****P < 0.0001). All data points are the mean from 
technical triplicates. (D) Schematic representation of the lineage tracing experiment for ductular origin. Eight-week-old Atg7flox/flox; Ptenflox/flox; Rosa26mTmG/mTmG mice were 
infected with hepatocyte-specific Cre-expressing adenovirus (AAV8-TBG-Cre) and aged for 40 days. Rosa26mTmG, Rosa26LoxP-Tomato-Stop-LoxP-GFP. (E) Representative IHC analysis 
of GFP, tdTomato and SOX9 staining on paraffin-embedded serial sections of liver from Atg7flox/flox; Ptenflox/flox; Rosa26mTmG/mTmG mice 40 days after infection with AAV8-Cre 
or the vehicle control (AAV8-null). Scale bars, 20 m.
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our data establish that autophagy prevents dedifferentiation of he-
patocytes into ductular LPCs.
HCCs originate from ductular LPCs in  
autophagy-deficient livers
ATG7-deficient livers develop HCCs at around 1 year of age (20). 
Since the ductular reaction is an early event following autophagy 
inhibition to regenerate the liver and ductular reactive cells express 
stem cell markers (Fig. 3A and fig. S3, A to C) found in cancer stem 
cells from HCC (40), we hypothesized that ductular LPCs form 
HCCs in autophagy-deficient livers. To test this, we first assessed 
whether autophagy-deficient HCCs retain the expression of the 
duct marker SOX9, and we noted the presence of two distinct 
hepatocyte populations (SOX9+ and SOX9−) in the normal region 
surrounding liver HCCs, with SOX9+ hepatocytes found adjacent to 
ductular structures (Fig. 4A). We found that hepatocytes forming 
HCCs preserved the ductular marker SOX9 (Fig. 4A). To further 
evaluate the role of the ductular reaction in tumorigenesis, we 
infected Alb-Cre+; Atg7fl/fl; Pten+/fl and WT mice with the AAV8-
TBG-GFP adenovirus at 6 weeks of age to label hepatocytes with 
GFP (Fig. 4B). At this age, the ductular reaction is occurring in 
autophagy-deficient livers, which allows us to distinguish and dis-
criminate between resident hepatocytes (GFP+) and ductular reac-
tive cells (GFP−) following AAV8-TBG-GFP infection to trace 
their role in tumorigenesis. First, we confirmed that at 7 days 
after AAV8-TBG-GFP infection, SOX9+ LPCs were GFP−, while 
hepatocytes (SOX9−) expressed GFP in autophagy-deficient livers 
(Fig. 4C), confirming that ductular LPCs are not expressing GFP 
following AAV8-TBG-GFP infection. We then assessed the expression 
of GFP in autophagy-deficient HCCs 100 days after AAV8-TBG-
GFP infection. This revealed that tumors forming in Alb-Cre+; Atg7fl/fl; 
Pten+/fl livers expressed no GFP in comparison to the surrounding 
normal hepatocytes, which retained GFP expression (Fig.  4D), 
highlighting that the ductular cells initiate tumorigenesis in autophagy- 
deficient livers. We also found that high expression of SOX9 cor-
relates with a decreased survival in human HCCs (Fig. 4E). Together, 
our data establish that ductular LPCs, formed early upon autophagy 
deficiency, ultimately lead to the generation of HCCs in autophagy- 
deficient livers.
Autophagy loss in the liver enhances a YAP/TAZ signature 
within ductular LPCs
Blocking the formation of the ductular reaction would be beneficial 
in preventing human HCC (41). YAP and TAZ are transcriptional 
coactivators essential in controlling organ size (42), hepatocyte de-
differentiation (31), stemness (43), and liver tumorigenesis (44, 45). 
The Hippo pathway regulates the activation of YAP and TAZ, and 
phosphorylation of both coactivators primes them for degradation. 
As our autophagy-deficient liver model develops severe hepato-
megaly (Fig.  1D and fig. S1D), dedifferentiates hepatocytes into 
ductular LPCs (Figs. 2 and 3 and figs. S2 and S3), and induces tum-
origenesis, we next investigated whether YAP and TAZ are active in 
early-stage autophagy-deficient livers exhibiting ductular reaction. 
First, we compared the protein levels of the inactive forms of YAP 
and TAZ (phosphorylated YAP and phosphorylated TAZ), with the 
levels of total YAP and total TAZ (active forms) in 4- to 5-week-old 
livers (Fig. 5A). We noticed that the ratio of phosphorylated YAP 
and phosphorylated TAZ was reduced in autophagy-deficient 
livers in comparison to WT counterparts (Fig. 5A), highlighting that 
unphosphorylated YAP and unphosphorylated TAZ accumulate in 
autophagy-deficient livers undergoing ductular reaction.
To evaluate whether YAP and TAZ are functionally active in 
autophagy-deficient livers, we tested for the expression of YAP/TAZ 
transcriptional targets in 4- to 5-week-old livers. We found that 
mRNA levels of connective tissue growth factor (Ctgf ), amphireg-
ulin (Areg), and cysteine-rich angiogenic inducer 61 (Cyr61), three 
YAP/TAZ target genes (46, 47), were all significantly up-regulated 
in autophagy-deficient livers (Fig. 5B and fig. S4A). At the protein 
level, CTGF was increased in total liver lysates of all autophagy- 
deficient conditions (Fig. 5A). Next, we assessed the localization of 
YAP and TAZ in 4- to 5-week-old autophagy-deficient livers and 
observed that both YAP and TAZ strongly accumulated in the ductular 
cells, whereas YAP and TAZ were found in the bile duct and the canal 
of Hering of WT counterparts (Fig. 5C and fig. S4B). Collectively, 
our data therefore indicate that autophagy loss in hepatocytes triggers 
a YAP/TAZ signature within the ductular LPC population.
TAZ is not degraded by autophagy
YAP is turned over not only by the proteasome (48, 49), but also by 
autophagy as shown in recent reports (20, 50). As TAZ is a YAP 
homolog, we next wondered whether TAZ accumulation and acti-
vation in our autophagy-deficient livers were due to blockage of 
autophagy- mediated degradation of TAZ. To test more directly 
whether TAZ is degraded by autophagy, we first deleted ATG7 or 
ATG5 expression in the liver cancer cell lines HLE and Huh7 using 
the CRISPR-Cas9–mediated gene disruption system. Next, we treated 
each cell line with Earle’s balanced salt solution (EBSS), to induce 
starvation-mediated autophagy, in combination with or without 
200 nM bafilomycin A1 (Baf) for 2 hours to prevent lysosomal deg-
radation of autophagosomes. We checked for the efficient disrup-
tion of ATG7 or ATG5 expression following lenti-CRISPR infection 
in HLE (fig. S5A) and Huh7 (fig. S5B), and we analyzed the conver-
sion of microtubule-associated protein 1A/1B-light chain 3 (LC3)–I 
(diffuse form in the cytosol) into LC3-II (lipidated form attached to 
autophagosomes), to confirm loss of autophagy. Examination of 
TAZ revealed that its levels did not change upon starvation-induced 
autophagy (EBSS), blockage of lysosomal autophagy degradation 
[Dulbecco’s modified Eagle’s medium (DMEM) + Baf and EBSS + Baf], 
or disruption of ATG7/ATG5 (ATG7CRISPR/ATG5CRISPR) in HLE 
and Huh7 cells (fig. S5, A and B). Unexpectedly, we also observed 
that not only YAP levels accumulated under EBSS only and EBSS 
and Baf conditions but also this occurred in ATG7CRISPR/ATG5CRISPR 
cells, indicating that this was an autophagy-independent effect. To-
gether, our data indicate that TAZ and YAP are not directly turned 
over by autophagy in liver cells and that the accumulation of YAP 
and TAZ in autophagy- deficient livers is not the result of the inhi-
bition of the autophagy degradation pathway but instead is due to 
the expansion of ductular cells in vivo, which are known to express 
YAP and TAZ (Fig. 5 and fig. S4) (51).
YAP and TAZ deletion blocks ductular cell formation 
and tumorigenesis in autophagy-deficient livers
Deletion of YAP partially rescued hepatomegaly, fibrosis, and tum-
origenesis induced by autophagy blockage in the liver (20). As a 
YAP homolog, TAZ can compensate YAP activity if the latter is lost 
(52). Since we observed in our model that YAP and TAZ are activated 
within the ductular LPC population, we hypothesized that deleting 
both YAP and TAZ might prevent the early ductular reaction and 
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Fig. 4. ATG7-deficient tumors originate from hepatocytes-derived LPCs. (A) IHC analysis of the duct marker SOX9 on Alb-Cre+; Atg7fl/fl; Pten+/fl livers from 140-day-old 
mice. The red dashed line separates tumor (T) from normal tissue (NT) in the liver. Red and green rectangles outline SOX9+ and SOX9− region in normal tissue, respective-
ly. Scale bar, 100 m. (B) Schematic representation of lineage tracing for tumor origin. Six-week-old Alb-Cre+; Atg7fl/fl; Pten+/fl and WT mice were infected with hepato-
cyte-specific GFP-expressing adenovirus (AAV8-TBG-GFP) and aged for either 7 or 100 days. (C) Immunofluorescence (IF) analysis of GFP and SOX9 on Alb-Cre+; Atg7fl/fl; 
Pten+/fl and WT livers 7 days following AAV8-TBG-GFP infection. 4′,6-diamidino-2-phenylindole (DAPI) stains nuclei. Scale bars, 75 m. (D) IHC analysis of GFP on Alb-Cre+; 
Atg7fl/fl; Pten+/fl or WT livers 100 days following AAV8-TBG-GFP infection. The red dashed line separates tumor from normal tissue in the liver. Scale bars, 100 m. 
(E) Kaplan-Meier analysis comparing overall survival between high and low SOX9 mRNA expression in human liver cancer data (The Cancer Genome Atlas Liver 
Hepatocellular Carcinoma). Each group represents 20th lower and 20th higher percentile (n = 72 per group).
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subsequent HCC formation in autophagy-deficient livers. First, we 
evaluated whether TAZ has a role in the phenotype of autophagy- 
deficient livers. To test this, we crossed Wwtr1flox/flox (encoding 
TAZ) mice (53) with our liver-specific autophagy-deficient model, 
and we observed that loss of TAZ significantly reduced liver size of 
4- to 5-week-old autophagy-deficient livers (Fig. 6A and fig. S6A). 
Next, we found that TAZ loss also significantly reduced the accu-
mulation of activated -SMA+ hepatic stellate cells and collagen 
deposition in 4- to 5-week-old autophagy-deficient livers (Fig. 6B 
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Fig. 5. YAP and TAZ are active in LPCs of ATG7-deficient livers. (A) Immunoblotting analysis of phosphorylated YAP (p-YAP), total YAP, phosphorylated TAZ (p-TAZ), 
total TAZ, CTGF, ATG7, and PTEN from 4- to 5-week-old total liver lysates. Extracellular signal–regulated kinase 2 (ERK2) was used as the loading control. (B) Quantitative 
RT-PCR analysis of the YAP/TAZ targets Ctgf, Cyr61, and Areg mRNA isolated from 4- to 5-week-old livers. 18S was used as the internal amplification control. Data are means ± 
SD of three mice per group and were analyzed by one-way ANOVA with Dunnett correction for multiple comparison tests (*P < 0.05, **P < 0.01, and ***P < 0.001). All data 
points are the mean from technical triplicates. (C) IHC analysis of YAP and TAZ on paraffin-embedded sections of livers from 4- to 5-week-old mice. Scale bars, 50 m.
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Fig. 6. TAZ deletion impairs hepatomegaly, hepatic stellate cell activation, fibrosis, and tumorigenesis in ATG7-deficient livers. (A) Liver-to-body weight ratio in 
4- to 5-week-old mice. Data are means ± SD of three mice per group and were analyzed by unpaired two tailed t test (**P < 0.01). (B) IHC analysis of hepatic stellate cell 
activation (-SMA), collagen deposition (Sirius Red), duct markers (SOX9 and panCK), and liver stem cell marker EpCAM on paraffin-embedded sections of livers from 4- to 
5-week-old mice. Scale bars, 50 m. Left: Representative staining. Right: Quantifications. Data are mean ± SD of three mice per group and were analyzed by unpaired 
two-tailed t test (*P < 0.05, **P < 0.01, and ***P < 0.001). All data points are the mean from five pictures per mouse. (C) Macroscopic pictures of Alb-Cre+; Atg7fl/fl; Pten+/fl 
(top) and Alb-Cre+; Atg7fl/fl; Pten+/fl; Tazfl/fl (Alb-Cre+; 7fl/fl; P+/fl; T−/−) (bottom) liver in 140-day-old mice. (D) Quantification of tumor numbers in Alb-Cre+; Atg7fl/fl; Pten+/fl and 
Alb-Cre+; Atg7fl/fl; Pten+/fl; Tazfl/fl at 140 days. Data are means ± SD of five mice per group and were analyzed by unpaired two-tailed t test (***P < 0.001). (E) Kaplan-Meier 
analysis comparing overall survival between Alb-Cre+; Atg7fl/fl; Pten+/fl and Alb-Cre+; Atg7fl/fl; Pten+/fl; Tazfl/fl mice (n = 5 males and n = 5 females per group). Data were ana-
lyzed by log-rank Mantel-Cox test (****P < 0.0001).
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activation and fibrosis in our model. In addition, TAZ loss signifi-
cantly decreased SOX9+, panCK+, and EpCAM+ cells in 4- to 
5-week-old autophagy-deficient livers (Fig. 6B and fig. S6B), high-
lighting that TAZ loss hinders the formation of ductular LPCs upon 
autophagy deficiency in the liver. We next compared tumor forma-
tion between Alb-Cre+; Atg7fl/fl; Pten+/fl or Alb-Cre+; Atg5fl/fl; Pten+/fl 
and Alb-Cre+; Atg7fl/fl; Pten+/fl; Tazfl/fl or Alb-Cre+; Atg5fl/fl; Pten+/fl; 
Tazfl/fl in 140-day-old livers and noted that TAZ deletion caused a 
highly significant decrease in tumorigenesis in autophagy-deficient 
livers (Fig. 6, C and D, and fig. S6, C and D) that was accompanied 
by a significant increase in the survival of autophagy-deficient mice 
(Fig. 6E and fig. S6E). Last, we evaluated whether TAZ has a role in 
the proliferation of ductular LPCs. We found that TAZ loss did not 
impair the number of Ki-67+ proliferative LPCs in 4- to 5-week-old 
autophagy-deficient livers (fig. S7).
To evaluate whether there was any redundancy between YAP and 
TAZ in our model, we crossed Yap1flox/flox mice (53) to our liver- 
specific (Alb-Cre) autophagy- and TAZ-deficient model to evaluate 
the effect of YAP/TAZ double knockout on the ductular reaction 
and tumorigenesis of autophagy-deficient livers. Unexpectedly, we 
observed that 40% (9 of 22 mice) of YAP-deficient mice developed 
jaundice within 6 to 8 weeks regardless of Atg7, Atg5, Pten, or Wwtr1 
genotype. This is likely because YAP is highly expressed in the bile 
duct of WT mice (Fig. 5C and fig. S4B), and the Albumin promoter 
driving Cre recombinase expression is expressed in hepatoblasts, 
the embryonic progenitor cells generating hepatocytes and cholan-
giocytes (54). YAP deletion in our Albumin-Cre model can therefore 
impair cholangiocyte function in the bile duct leading to acute 
jaundice. To overcome this phenotype for long term studies, we used 
AAV8-TBG-Cre adenovirus to induce Cre recombination more spe-
cifically in the hepatocytes of our Atg7flox/flox; Ptenflox/flox; Yap flox/flox; 
Tazflox/flox model (Fig. 7A). First, we assessed the effect of YAP/TAZ 
deletion on the hepatomegaly and ductular reaction of autophagy- 
deficient livers 3 weeks following AAV8-TBG-Cre recombination 
and confirmed the recombination of Atg7, Pten, Yap, and Wwtr1 
alleles in AAV8-TBG-Cre–infected livers (fig. S8). We found that 
although YAP or TAZ deletion significantly reduced hepatomegaly 
of autophagy-deficient livers (Fig. 7B), YAP/TAZ double knockout 
mice significantly restored liver size to that observed in nonrecom-
bined counterparts infected with the AAV8-TBG-null adenovirus 
(Fig. 7B). In addition, we noted that while the individual deletion of 
Yap or Taz significantly impaired the formation of SOX9+ cells in 
autophagy-deficient livers (Fig. 7, C and D), only YAP/TAZ codeletion 
completely blocked the formation of SOX9+ cells in autophagy- 
deficient livers (Fig. 7, C and D). In this AAV8-TBG-Cre model, 
Atg7/; Pten/ mice had to be culled because of hepatomegaly and 
did not develop tumors at humane end point. To evaluate the role 
of YAP/TAZ loss in the tumorigenesis of autophagy-deficient livers, 
we infected Atg7flox/flox; Pten+/flox; Yapflox/flox; Tazflox/flox with AAV8-
TBG-Cre adenovirus and assessed tumor formation 140 days fol-
lowing AAV8 infection (Fig. 7E). We observed that while Yap or 
Taz deletion significantly impaired tumorigenesis in autophagy- 
deficient livers (Fig. 7, F and G), only YAP/TAZ codeletion com-
pletely prevented tumor formation (Fig. 7, F and G). Our data 
therefore show that deleting YAP and TAZ suppresses the ductular 
reaction and tumorigenesis of autophagy-deficient livers. However, in 
this context, we observed functional redundancy between YAP and 
TAZ, and only the combined deletion of both these genes could 
revert the effects on tissue overgrowth and tumor development.
DISCUSSION
We report a new model for extensive ductular reaction upon dele-
tion of ATG5 or ATG7 and PTEN in the murine liver. Although Pten- 
deficient livers develop steatosis and HCC (37), we observed that 
hepatic Pten deletion alone did not initiate liver damage, inflamma-
tion, hepatic stellate cell activation, fibrosis, or a ductular reaction 
in young livers, but these effects were observed on hepatic deletion 
of ATG5 or ATG7. ATG5 and ATG7 are two proteins that are 
essential for the stage of autophagy that involves LC3 conjugation. 
ATG5 and ATG7 are also important for two other processes that 
involve the LC3 conjugation machinery: LC3-associated phagocyto-
sis (LAP) (55) and LC3-associated endocytosis (LANDO) (56). We 
consider, however, that the core observations in our study relating 
to tumor development and liver injury are connected to autophagy, 
as previous studies have shown that they can be reversed by con-
comitant deletion of the autophagy adapter protein p62 (11, 22, 57), 
and autophagy adapter proteins are not thought to be involved in 
LAP or LANDO (58). We cannot fully discount that some of the 
effects we observe on deletion of ATG5 or ATG7 may be related to 
LAP or LANDO rather than autophagy or a combination thereof. 
Future studies to clarify this point using deletion of other factors 
such as FIP200 or ATG13 that are involved in autophagy, but not 
LAP and LANDO (59–62), would certainly be merited to investigate 
this possibility.
Autophagy is impaired in Pten-deficient mice due to mTORC1 
activation; however, autophagy is not blocked in Pten-deficient 
livers (63). LC3 is still conjugated to phosphatidylethanolamine 
leading to autophagosome and autolysosome formation when Pten 
expression is lost (63). This dictates an important role for autophagy 
in hepatocytes to prevent the microenvironmental remodeling and 
ductular reaction in healthy livers, with Pten cooperating with the 
autophagy-specific phenotype. Pten loss induces cellular senescence 
to protect from tumorigenesis in different models (64, 65). However, 
we noticed the presence of apoptotic hepatocytes following autoph-
agy abrogation and Pten deletion. The extent of injury in hepatocytes 
determines their fate toward senescence or cancer (66). Acute injury 
in hepatocytes results in senescence (67), while chronic injury does 
not activate senescence in hepatocytes, ultimately leading to HCC 
(66). Autophagy degrades damaged mitochondria, a process named 
mitophagy, to maintain cellular homeostasis. In hepatocytes, loss of 
autophagy leads to ROS accumulation, damaged mitochondria, 
and dysfunction (11, 22, 68, 69). We suggest that the persistence of 
chronic damage and defects in damaged mitochondria clearance by 
mitophagy drive apoptosis and tumorigenesis in our autophagy- and 
Pten-deficient livers.
In our autophagy- and Pten-deficient model, we observed that 
following liver injury, hepatocytes dedifferentiate into ductular 
LPCs. This ductular reactive phenotype is not unique to the loss of 
autophagy as it has previously been observed in animal models subjected 
to diet modification, e.g., a diet enriched in 3,5-diethoxycarboncyl- 
1,4-dihydrocollidine (70) or choline-deficient, ethionine-supplemented 
diet (71). This indicates that the ductular reaction is likely to be a 
secondary effect of autophagy inhibition due to liver damage caused 
by autophagy loss. The origin of the ductular reaction in rodents 
is still controversial, with reports indicating the role of biliary cells 
(28, 29) or hepatocytes (30, 31) in forming LPCs with the capacity 
for generating new hepatocytes upon liver injury. Here, we show in 
a genetically modified mouse model that ductular reactive cells arise 
from mature hepatocytes upon injury induced by autophagy deficiency. 
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Fig. 7. YAP and TAZ cooperate to drive the duct-induced tumorigenesis in ATG7-deficient livers. (A) Schematic representation. Eight-week old Atg7fl/fl; Ptenfl/fl ± 
Yapfl/fl (Yfl/fl) and/or Tazfl/fl (Tfl/fl) mice were infected with AAV8-TBG-Cre and aged for 3 weeks before hepatomegaly and ductular reaction analysis. (B) Liver-to-body weight 
ratio in mice 3 weeks after AAV8 infection. Data are means ± SD of five mice per group and were analyzed by one-way ANOVA with Tukey correction for multiple compar-
ison tests (*P < 0.05, ***P < 0.001, and ****P < 0.0001). (C) IHC analysis of the duct marker SOX9 on paraffin-embedded sections of livers from mice 3 weeks after AAV8 
infection. Scale bars, 50 m. (D) Quantification of SOX9 from (C). Data are means ± SD of five mice per group and were analyzed by one-way ANOVA with Tukey correction 
for multiple comparison tests (****P < 0.0001). All data points are the mean from five pictures per mouse. (E) Schematic representation. Eight-week-old Atg7fl/fl; Pten+/fl; 
Yapfl/fl and/or Tazfl/fl mice were infected with AAV8-TBG-Cre and aged for 140 days before tumor analysis. (F) Macroscopic pictures from 140 days after AAV8-Cre livers. 
(G) Quantification of tumor numbers in 140 days after AAV8-Cre livers. Data are means ± SD of five mice per group and were analyzed by one-way ANOVA with Tukey 
correction for multiple comparison tests (*P < 0.05, **P < 0.01, and ****P < 0.0001). All data points are the mean from five pictures per mouse. Xfl/fl, AAV8-null infected; X/, 
AAV8-Cre infected.
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The cellular plasticity of human hepatocytes can also generate duct-
ular cells in a transplantation mouse model (30), strengthening the 
hepatocyte origin of the ductular reaction in human liver diseases.
The plastic differentiation program of the ductular reaction for 
liver regeneration is defined by the origin of the injuries. Following 
bile duct injury, resident LPCs/biliary cells (26) and hepatocyte- 
derived LPCs (72) regenerate biliary cells. When hepatocyte function 
is impaired, resident LPCs/biliary cells (28, 29, 73) or hepatocyte- 
derived LPCs (30, 31, 74) generate new hepatocytes. The decision to 
recruit biliary cells or hepatocytes during the ductular reaction re-
mains elusive, and future studies will be required to shed further 
light on this mechanism.
Autophagy loss has been previously shown to give rise to HCC 
in mice (20). Our results suggest that the hepatocyte-derived ductu-
lar reaction gives rise to HCC in autophagy-deficient livers. While 
some studies conclude that the ductular reaction is not involved in 
liver carcinogenesis (34, 35, 74), other studies do report a role for 
the ductular reaction in initiating HCCs (32, 33). Although all these 
studies recombine LPCs for lineage tracing, they differ with respect 
to the timing between the induction of LPC labeling and the start of 
the injury. Recombination of LPCs for lineage tracing before induc-
ing liver injury (34, 35, 74) does not label hepatocyte-derived LPCs, 
excluding them from the lineage tracing of HCCs. In contrast, re-
combination of LPCs for lineage tracing following liver injury results 
in LPC-derived HCCs (32, 33). In our autophagy- and Pten-deficient 
model, we report that hepatocyte-derived LPCs generate SOX9+ 
hepatocytes that give rise to HCC. The ability of LPCs to induce 
tumorigenesis has been controversial since it is generally ac-
cepted that HCC originates from hepatocytes. Here, we reconcile these 
findings by showing that HCC does originate from hepatocytes, 
but these hepatocytes, early upon liver injury, dedifferentiate into 
LPCs to attempt to regenerate liver function, before transforming 
into HCC.
In human liver diseases, the accumulation of LPCs is observed in 
nonalcoholic steatohepatitis–induced cirrhosis preceding HCC (75), 
and the presence of peritumoral ductular reaction is a poor prognostic 
factor for human HCC after resection (76), indicating the importance 
of targeting the ductular reaction in human liver diseases. The gene 
signature of autophagy-deficient mice is similar to the human tran-
scriptomes of nonalcoholic fatty livers (20), and rat livers from rats 
fed a high-fat diet reduce their autophagy function (77). Restoring 
autophagy could therefore be a beneficial treatment in injured livers 
harboring a ductular reaction.
Mechanistically, we report that YAP and TAZ cooperate to drive 
hepatocyte dedifferentiation and tumorigenesis in autophagy-deficient 
livers. Unlike a previous study on YAP (20), we uncovered that TAZ 
also plays a role in promoting hepatomegaly, ductular reaction, 
stromal activation, fibrosis, and tumorigenesis in autophagy-deficient 
livers. TAZ deletion alone, similar to YAP deletion alone (20), only 
impaired carcinogenesis in autophagy-deficient livers. However, TAZ 
loss did not impair the proliferative outgrowth of the ductular LPC 
population. Here, we speculate that TAZ is involved in the differen-
tiation switch in our model as its homolog YAP can directly drive 
hepatocyte dedifferentiation (31), and, more recently, YAP/TAZ 
have been described as regulators of stemness and cell plasticity in 
glioblastoma (78). We found that YAP and TAZ are not directly 
turned over by autophagy and that their accumulation in the ab-
sence of autophagy in vivo is associated with the increased presence 
of ductular cells, which are known to express YAP and TAZ (79). 
YAP and TAZ are mechanosensors and mechanotransducers (80), 
and their activation is linked to the stiffness of the extracellular ma-
trix (81). As we noted a significant increase in extracellular matrix 
remodeling and fibrosis (Fig. 1E and fig. S1, F and G) correlating with 
a significant increase in YAP+/TAZ+ ductular LPCs in our models, 
we suggest that YAP and TAZ are also activated in response to 
the microenvironment changes following autophagy and PTEN 
deletion in the liver. Building on these findings, we observed that 
only the combined deletion of YAP and TAZ prevented the emer-
gence of hepatocyte-derived LPCs that initiate tumorigenesis in 
autophagy-deficient livers. Our study uncovered a role for auto-
phagy in suppressing the emergence of hepatocyte-derived duct-
ular LPCs that can give rise to HCCs via concomitant activation 
of YAP and TAZ.
MATERIALS AND METHODS
Animal experiments
Male and female animals were housed in a pathogen-free environ-
ment and kept under standard conditions with a 12-hour day/night 
cycle and access to food and water ad libitum. All in vivo experi-
ments were carried out under guidelines approved by the Glasgow 
University Animal Welfare and Ethical Review Body and in accord-
ance with U.K. Home Office guidelines under license P54E3DD25. 
As described previously (82), Alb-Cre+ mice [RRID (research re-
source identifier): MGI:2176228] were crossed to Atg7fl/fl (68) (RRID: 
MGI:3590136) or Atg5fl/fl (83) (RRID: MGI:3612279) and Ptenfl/fl 
(84) (RRID: MGI:2182005) to generate the different combinations 
on a mixed background. Subsequently, Atg7fl/fl; Ptenfl/fl and Atg5fl/fl; 
Ptenfl/fl mice were crossed to Yap1fl/fl; Wwtr1fl/fl (the Jackson labo-
ratory, stock 030532, RRID: IMSR_JAX:030532) (53) animals to 
generate all the different combinations. Experimental cohort (males 
and females) sizes were based on previous similar studies that have 
given statistically significant results while also respecting the limit-
ed use of animals in line with the 3R system: replacement, reduc-
tion, and refinement. All treatment studies were randomized but 
did not involve blinding. Genotyping was performed by Transne-
tyx. To lineage trace the ductular cell origin, we crossed our model 
with the Rosa26-mtdTomato-mEGFP mouse (the Jackson laboratory, 
stock 007576, RRID: IMSR_JAX:007576) (85).
In AAV8 studies, AAV8 recombination was performed as previ-
ously described (67). Briefly, viral particles [2 × 1011 genomic copies per 
mouse] of AAV8.TBG.PI.Cre.rBG (Addgene, catalog no. 107787-AAV8), 
AAV8.TBG.PI.eGFP.WPRE.bGH (Addgene, catalog no. 105535-AAV8), 
or AAV8.TBG.PI.Null.bGH (Addgene, catalog no. 105536-AAV8) were 
injected in 6-week-old (AAV8-GFP and AAV8-null) or 8-week-old 
(AAV8-Cre and AVV8-null) mice via tail vein in 100 L of phosphate- 
buffered saline (PBS).
Animal tissue harvesting and serum analysis
Mice were euthanized by CO2 inhalation followed by cervical dislo-
cation, and blood was harvested by cardiac puncture in accordance 
with U.K. Home Office guidelines. Tissues were weighed and stored 
immediately at −80°C or in paraffin blocks after fixation in 10% for-
malin (in PBS) for 24 hours, followed by dehydration in 70% etha-
nol before embedding. Blood samples (EDTA-plasma and serum) 
were stored at −80°C following 10-min centrifugation at 900g at 
4°C. Serum was sent to the Veterinary Diagnostic Services (Univer-
sity of Glasgow) for ALT, AST, ALP, and GGT analyses.
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Plasma AFP levels
Plasma AFP levels were assessed using the enzyme-linked immuno-
sorbent assay (ELISA) kit (catalog no. ab210969) according to the 
manufacturer’s instruction. Each sample was analyzed in triplicate.
Immunohistochemistry and immunofluorescence
For immunohistochemical (IHC) or immunofluorescence (IF) studies, 
paraffin-embedded sections were deparaffinized, rehydrated, and 
heated to 95° to 97°C either in Lab Vision Citrate Buffer for heat- 
induced epitope retrieval (pH 6.0) (Thermo Fisher Scientific, catalog 
no. 12638286), EnVision FLEX Target Retrieval Solution, High pH 
(Agilent, catalog no. K8004), BOND Epitope Retrieval Solution 2 (ER2) 
(Leica, catalog no. AR9640), or Antigen Unmasking Solution, Citric 
Acid Based (Vector Laboratories, catalog no. H-3300) for antigen 
retrieval, depending on the primary antibody used. Primary anti-
bodies used for IHC analyses: Ly6G (Bio X Cell, catalog no. BE0075-
1, RRID: AB_1107721, rat, ER2; 1:60,000), -SMA (Sigma-Aldrich, 
catalog no. A2547, RRID: AB_476701, mouse, citric acid; 1:25,000), 
CC3 (Asp175, Cell Signaling Technology, catalog no. 9661, 
RRID: AB_2341188, rabbit, ER2; 1:500), SOX9 (Millipore, catalog no. 
AB5535, RRID: AB_2239761, rabbit, high pH; 1:500), CK19 (Novus, 
catalog no. NB100-687, RRID: AB_2265512, rabbit, high pH; 1:100), 
panCK (Lab Vision, catalog no. MS-343-P, RRID: AB_61531, 
mouse, Citric acid; 1:100), EpCAM (Abcam, catalog no. ab71916, 
RRID: AB_1603782, rabbit, high pH; 1:1500), CD133 (Abcam, 
catalog no. ab19898, RRID: AB_470302, rabbit, citrate pH 6; 1:200), 
CD44 (BD Biosciences, catalog no. 550538, RRID: AB_393732, rat, 
ER2; 1:300), GFP (Cell Signaling Technology, catalog no. 2555, 
RRID: AB_10692764, rabbit, ER2; 1:600), red fluorescent protein 
(Rockland, catalog no. 600-401-379, RRID: AB_2209751, rabbit, high 
pH; 1:1000), YAP (Cell Signaling Technology, catalog no. 4912, RRID: 
AB_2218911, rabbit, high pH; 1:50), WW domain containing transcrip-
tion regulator 1 (WWTR1)/TAZ (Sigma-Aldrich, catalog no. HPA007415, 
RRID: AB_1080602, rabbit, high pH; 1:100), and Ki-67 (Cell Signaling 
Technology, catalog no. 12202, RRID: AB_2620142, rabbit, ER2; 
1:1000). Primary antibodies were incubated with sections for 40 min 
at room temperature or overnight at 4°C. For IHC analysis, primary 
antibodies were detected using mouse or rabbit EnVision+ System 
kits (Agilent, catalog no. K4001 and K4006) or ImmPRESS horse-
radish peroxidase (HRP) goat anti-rat immunoglobulin G (IgG) 
polymer detection kit (Vector Laboratories, catalog no. MP-7404) 
and 3,3′-diaminobenzidine substrate (Agilent, catalog no. K4011). 
Slides were then counterstained with hematoxylin solution. Images 
were obtained on a Zeiss AX10 (light microscopy) at a ×20 or ×40 
magnification.
For IF analysis, SOX9/GFP immunofluorescent primary anti-
bodies were applied sequentially. First, slides were incubated with a 
chicken polyclonal GFP antibody (Abcam, catalog no. ab13970, 
RRID: AB_300798, citrate; 1:200) overnight at 4°C and was detected 
using a biotinylated goat anti-chicken (Vector Laboratories, catalog 
no. BA-9010, RRID: AB_2336114; 1:200) coupled to Avidin-HRP 
(Vector Laboratories, PK-7100) and a PerkinElmer TSA Plus Cyanine 3 
signaling amplification kit (NEL744B001KT; 1:50). This was 
followed by a second antigen retrieval to denature any antibodies in 
the tissue. Slides were then incubated with a rabbit monoclonal SOX9 
antibody (Abcam, catalog no. ab185230, RRID: AB_2715497, citrate; 
1:500) overnight at 4°C and detected using a donkey anti-rabbit 
Alexa Fluor 488 secondary antibody (Molecular Probes, catalog 
no. A-21206, RRID: AB_2535792; 1:200). Slides were then counterstained 
with 4′,6-diamidino-2-phenylindole (DAPI). Images were obtained 
on a Zeiss 710 confocal microscope at a ×20 magnification. For 
collagen staining, sections were rehydrated and then immersed in 
Picro Sirius Red solution [0.1% Direct Red 80 (Sigma- Aldrich, 
41496LH) and 0.1% Fast Green FCF (Raymond Lamb, S142-2) 
diluted in aqueous picric acid solution] for 2 hours.
Cell culture
HLE and Huh7 were grown in DMEM (Gibco, 21969-035) supple-
mented by 10% fetal bovine serum (FBS; Gibco, 10270-106), 2 mM 
glutamine (Gibco, 25030-032), streptomycin (100 g/ml), and 
penicillin (100 U/ml; Gibco, 15140-122) (complete DMEM) at 
37°C and 5% CO2. For starvation-induced autophagy experiments, 
cells were washed twice in PBS and starved in EBSS (Sigma-Aldrich, 
E2888) containing or not 200 nM Baf (LC Labs, B-1080) for 2 hours. 
HLE and Huh7 cell lines were provided by T. Bird.
Lentivirus production and infection for CRISPR
Lentiviruses were produced using human embryonic kidney (HEK) 
293T cells using calcium/phosphate transfection protocol. Cells 
were transfected overnight with lentiviral, packaging, and envelope 
plasmids (pPAX2 and pVSVG). The following day, media were re-
placed by complete DMEM containing 20% FBS for 24 hours. Then, 
virus-enriched media were collected, filtered (0.45 m), supplemented 
with polyprene (4 g/ml; Sigma-Aldrich, H9268), and transferred 
to recipient cells. In the meantime, HEK293T cells were kept in 
DMEM containing 20% FBS for an additional 24 hours to perform 
a second round of infection of recipient cells as described before. 
Last, infected cells were selected with puromycin (2 g/ml; Sigma- 
Aldrich, P9620) for 10 days. The following single-guide RNA se-
quences were used in this study: human ATG7, 5′-GAA GCT GAA 
CGA GTA TCG GC-3′ (86); human ATG5, 5′-AAG AGT AAG TTA 
TTT GAC GT-3′ (86); nontargeting control, 5′-GTA GCG AAC 
GTG TCC GGC GT-3′ (87).
Protein extraction and Immunoblotting
Livers were dissociated using a Precellys Evolution (Bertin Tech-
nologies) and lysed in 1% Triton X-100, 0.1% SDS, 50 mM Hepes 
(pH 7.5), 150 mM NaCl, 100 mM NaF, and 10 mM EDTA, sup-
plemented with Halt protease and phosphatase inhibitor cocktail 
(Thermo Fisher Scientific, catalog no. 87786). After 15-min centrif-
ugation at 12,000g at 4°C, the supernatant was removed, and the 
concentration of solubilized proteins was determined with the 
Pierce bicinchoninic acid assay (Thermo Fisher Scientific, catalog 
no. 23225). Protein lysates were separated by SDS–polyacrylamide 
gel electrophoresis with Criterion TGX Stain-Free precast gels (Bio-Rad) 
or the NuPAGE 4 to 12% bis-tris gel (Invitrogen) and blotted onto 
polyvinylidene difluoride membranes (Merck). Criterion TGX Stain- 
Free precast gels (Bio-Rad) were activated using the ChemiDoc 
(Bio-Rad) to detect total protein levels. Total protein level was mea-
sured before and after transfer. Western blot analysis was per-
formed according to the manufacturer’s instructions for Criterion 
TGX Stain-Free precast gels or for the NuPAGE 4 to 12% bis-tris gel 
(Invitrogen). The following antibodies were used at a dilution of 
1:1000 unless otherwise stated: p-YAP (Cell Signaling Technology, 
catalog no. 13008, RRID: AB_2650553), YAP (Cell Signaling Tech-
nology, catalog no. 4912, RRID: AB_2218911; 1:750), p-TAZ (Cell 
Signaling Technology, catalog no. 59971, RRID: AB_2799578), YAP/
TAZ (Cell Signaling Technology, catalog no. 8418, RRID: AB_10950494), 
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CTGF (Abcam, catalog no. ab125943, RRID: AB_2858254), ATG7 
(Cell Signaling Technology, catalog no. 8558, RRID: AB_10831194), 
PTEN (Cell Signaling Technology, catalog no. 9559, RRID: AB_390810), 
extracellular signal–regulated kinase 2 (ERK2; Santa Cruz Biotech-
nology, catalog no. sc-154, RRID: AB_2141292), LC3B (Cell Signaling 
Technology, catalog no. 2775, RRID: AB_915950), ATG5 (Cell 
Signaling Technology, catalog no. 12994, RRID: AB_2630393), 
glyceraldehyde-3-phosphate dehydrogenase (Abcam, catalog no. ab9485, 
RRID: AB_307275), anti-rabbit IgG HRP-linked (Cell Signaling 
Technology, catalog no. 7074, RRID: AB_2099233; 1:4000), and 
anti-mouse IgG HRP-linked (Cell Signaling Technology, catalog 
no. 7076, RRID: AB_330924; 1:4000).
Reverse transcription quantitative polymerase 
chain reaction
RNAs were extracted from livers using the RNeasy Mini Kit (QIAGEN, 
catalog no. 74101) and quantified using a NanoDrop200c (Thermo 
Fisher Scientific). Complementary DNAs (cDNAs) were produced 
using the High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific, 
catalog no. 4388950) according to the manufacturer’s instruction. 
Quantitative polymerase chain reactions (qPCRs) were performed 
using the DyNAmo HS SYBR Green qPCR Kit (Thermo Fisher Sci-
entific, catalog no. F-410) on a Step-One Plus (Applied Biosystems) 
as follows: 20 s at 95°C, followed by 40 cycles of 3 s at 95°C, and 30 s 
at 60°C. mRNA quantification was calculated using ∆Ct method. 
The following mouse primers were used: mouse Ctgf (QIAGEN, 
QT00174020), mouse Ctgf (QIAGEN, QT00096131), mouse Cyr61 
(QIAGEN, QT00245217), mouse Areg (QIAGEN, QT00112217), 
18S forward (5′-GTAACCCGTTGAACCCCATT-3′), and 18S re-
verse (5′-CCATCCAATCGGTAGTAGCG-3′).
Quantification and statistical analysis
For IHC studies, five representative pictures were taken per mouse 
and were analyzed using Fiji software. For all in vivo studies, data 
are shown as means ± SD. Sample normality was assessed by Shapiro- 
Wilk test. Statistical significances were determined by two-tailed 
unpaired Student’s t test for two-group comparison, two-way anal-
ysis of variance (ANOVA) with Tukey or Dunnett for multiple group 
comparison, and log-rank (Mantel-Cox) test for survival compari-
son using GraphPad Prism software. Results were considered statis-
tically different when *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 
0.0001 with ns indicating no significance.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/23/eabf9141/DC1
View/request a protocol for this paper from Bio-protocol.
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